Quarterly report pursuant to Section 13 or 15(d)

NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative)

v3.19.3
NATURE OF OPERATIONS AND BASIS OF PRESENTATION (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 07, 2019
Jan. 31, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
State of incorporation         Nevada  
Date of incorporation         Feb. 21, 2014  
Net loss     $ (855,230) $ (113,759) $ (1,363,158) $ (515,516)
Net cash used in operating activities         (765,571) $ (293,510)
Private Placements [Member] | Accredited Investors [Member]            
Proceeds from issuance of convertible notes         $ 791,939  
Trace Analytics [Member]            
Common stock purchase agreement, description the Company closed on a purchase of 520,410 shares of common stock of Trace Analytics, Inc., a Washington corporation (“Trace Analytics”), for an aggregate purchase price of $1,250,000, of which $750,000 was paid in cash and $500,000 was paid in shares of common stock of the Company. Trace Analytics is a cannabis testing laboratory. Immediately following the purchase, the Company held 51% of the issued and outstanding shares of common stock        
Issuance of common stock for cash, shares 520,410 520,410        
Aggregate purchase price of common stock $ 1,250,000 $ 1,250,000        
Purchase price of common stock paid in cash   $ 750,000        
Purchase price of common stock paid in shares   500,000        
Owned interest entity         51.00%